CERVICAL CANCER

This study is testing a new vaccine called PVX7 in 32 women with advanced cervical cancer who have finished their main treatment (surgery, radiation, or chemo). The goal is to see if the vaccine is safe and can boost the body's immune response against HPV, the virus that causes c…

This study tests a new drug called BMS-986340, alone or with other cancer treatments, in people with advanced solid tumors like lung, colon, or breast cancer. The goal is to find safe doses and check for side effects. About 1,100 adults with tumors that have worsened after standa…

This study tests whether a non-invasive physical plasma treatment can clear HPV infections from the cervix. About 50 adults with HPV will receive the treatment, and researchers will check if the virus is gone afterward. The goal is to find a new way to prevent cervical cancer cau…

This study follows 261 people with persistent, recurrent, or metastatic cervical cancer who are taking pembrolizumab (Keytruda) with or without bevacizumab (Avastin). Some participants may choose to stop pembrolizumab early if their tumor shrinks or disappears, while others conti…

This study tests a new drug called CR-001 in adults with advanced solid tumors that have spread. The goal is to find the safest dose and see if it can shrink tumors. About 290 people will take part in this early-phase trial.

This study is testing the drug T-DXd (Enhertu) in 100 adults with advanced HER2-positive solid tumors who have already tried other treatments and have no good options left. The goal is to see how well the drug works in real-world settings, including how many patients respond and …

This trial investigates whether collecting and storing a patient's own blood stem cells before chemoradiotherapy, then re-infusing them after treatment, can help rebuild healthy blood cells faster. The study includes 40 women with cervical cancer who are scheduled for chemoradiot…

This phase 3 trial tests whether adding the experimental drug sacituzumab tirumotecan (sac-TMT) to standard immunotherapy (pembrolizumab) and a targeted therapy (bevacizumab) helps people with metastatic cervical cancer live longer. About 1,000 participants whose cancer has sprea…

This study tests a new drug called XTX301 in people with advanced solid tumors that have not responded to standard treatments. The trial has two parts: first, finding a safe dose, and then testing that dose in specific cancer types. Researchers will monitor side effects and wheth…

This study tests a new treatment for people with advanced or recurrent cervical cancer linked to high-risk HPV. The treatment uses specially engineered immune cells (CC-EIEs) designed to target and attack the cancer. Participants receive several infusions of these cells, and rese…

This trial investigates whether specially engineered immune cells (CAR-T cells) can safely treat advanced or recurrent cervical cancer. The cells are designed to recognize and attack cancer cells that carry certain markers like GD2 or Mesothelin. The study involves 20 adults with…

This early-stage trial tests a new drug called LY4052031, which is designed to deliver a cancer-killing agent directly to tumor cells that have a protein called Nectin-4. The study includes 420 adults with advanced or metastatic solid tumors such as bladder, breast, lung, and oth…

This study tests a new drug, LY4170156, designed to attack cancer cells with a specific marker (folate receptor alpha). It is for people with advanced solid tumors like ovarian, lung, or breast cancer that have not responded to other treatments. The trial has two parts: first fin…

This early-stage trial explores whether injecting the immunotherapy drug nivolumab directly into lymph nodes before standard surgery is feasible and safe for people with cervical cancer. The study involves 12 participants and aims to see if this targeted approach can shrink tumor…

This study tests whether a shorter, 3-week course of radiation works as well as the standard 5-week course for women with locally advanced cervical cancer. About 396 women will be randomly assigned to one of the two schedules, both combined with chemotherapy. If the shorter sched…

This early-stage trial is testing a new type of immune cell therapy for people with advanced cancers that have a specific protein called KK-LC-1. The cancers being studied include stomach, breast, cervical, and lung cancer. Participants will receive chemotherapy followed by a sin…

This study tests whether a single infusion of a patient's own genetically engineered immune cells (E7 TCR-T cells) can shrink or eliminate HPV-related cancers before the patient receives standard treatment like chemo-radiation or surgery. The trial enrolls 15 adults with advanced…

This study tests a new immunotherapy for people with advanced HPV-related cancers, such as cervical, throat, anal, and penile cancers. Participants receive specially engineered immune cells designed to attack cancer cells carrying the HPV16 virus. The goal is to see if this treat…

This early-phase trial tests a new drug that delivers radiation directly to cancer cells carrying a specific protein called GRPR. The study includes 48 adults with advanced cancers like prostate, breast, lung, or colon cancer that have not responded to standard treatments. The ma…

This early-phase trial is testing an experimental oral drug called RGT-490 in about 63 adults with advanced solid tumors (including certain breast, ovarian, and endometrial cancers) that have a PIK3CA gene mutation and have stopped responding to standard treatments. The main goal…

This early-phase trial is testing a new drug called enzelkitug, alone or with standard immunotherapies, in people with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. A…

This Phase 2 trial tests an oral drug called BAY 2927088 (sevabertinib) in about 111 adults with advanced solid tumors that have HER2 gene mutations. The drug aims to block the abnormal HER2 protein and stop cancer growth. Participants take a 20 mg tablet daily in 3-week cycles u…

This study compares a new barbed suture (SYMMCORA) with a standard one (V-Loc) for closing the vaginal cuff after laparoscopic hysterectomy. The goal is to see if the new suture reduces stitching time without increasing complications. About 132 women having elective laparoscopic …

This phase 2 trial is testing an experimental drug called volrustomig, either alone or with chemotherapy, in people with advanced cervical, head and neck, esophageal, or mesothelioma cancers. The study aims to see if the drug can shrink tumors and how safe it is. About 257 partic…

This study looks at whether surgically removing para-aortic lymph nodes before standard chemoradiation can improve disease-free survival in people with stage IIIC1 cervical cancer. About 510 participants will be randomly assigned to either standard treatment or surgery plus tailo…

This study tests a new drug, TER-2013, in people with advanced solid tumors (like breast, ovarian, or lung cancer) that have specific genetic changes in the AKT/PI3K/PTEN pathway. The goal is to see if the drug is safe and can shrink tumors. About 205 participants will receive th…

This study tests two new drug combinations (DB-1311 with BNT327 or DB-1305) in 450 adults with advanced or metastatic solid tumors that have not responded to other treatments. The main goals are to check safety and see if tumors shrink. Participants must be in fairly good health …

This study tests a new drug called BNT326, given alone or with other cancer immunotherapies, in about 980 adults with advanced solid tumors that have spread or come back after prior treatment. The goal is to find the best dose and see if it is safe and effective. It is an early-s…

This study tests a new treatment called KSQ-004EX for people with advanced solid tumors that have not responded to standard therapies. The treatment uses a patient's own immune cells (tumor infiltrating lymphocytes) that are genetically modified to be more powerful against cancer…

This study tests whether adding the drug tarlatamab to standard radiation therapy is safe for people with cancers that have a protein called DLL3, including melanoma, lung cancer, and glioblastoma. About 30 adults with advanced or returning cancers will receive tarlatamab infusio…

This phase 2 trial is testing an experimental drug called patritumab deruxtecan (HER3-DXd) in 740 people with advanced solid tumors, including melanoma, lung, breast, and other cancers. The drug is given by IV every three weeks. The main goal is to see if the drug shrinks tumors.…

This study is testing a new experimental drug called GI-101, given alone or with pembrolizumab or lenvatinib, in people with advanced or metastatic solid tumors (cancers that have spread). The goal is to see if the drug is safe and can shrink or control tumors. About 317 adults w…

This study is for adults with certain cancers (like breast, lung, or ovarian) that are in complete remission but have persistently low platelet counts from past chemotherapy. It tests whether adding a vitamin A derivative (ATRA) to a standard platelet-boosting drug works better t…

This early-stage trial is testing a new drug called sigvotatug vedotin, alone or with other cancer medicines, in people with advanced solid tumors like lung, head and neck, and breast cancers. The study aims to find a safe dose and check for side effects. About 1,000 participants…

This early-phase trial tests a new drug, UCB4594, in people with advanced solid tumors that haven't responded to standard treatments. The drug is a monoclonal antibody that targets a protein called HLA-G on cancer cells, potentially helping the immune system attack them. The stud…

This early-stage study tests an experimental drug called IMGS-001 in about 105 people with advanced solid tumors that have come back or not improved after standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. The study has two parts: first, t…

This study tests a new drug called PYX-201 combined with pembrolizumab in people with advanced solid tumors that have not responded to other treatments. The goal is to find safe doses and see if the combination can shrink tumors. About 220 adults with certain cancers like head an…

This study is testing whether two drugs, pembrolizumab (Keytruda) and lenvatinib (Lenvima), can slow tumor growth in people with cervical cancer that has spread or come back. About 30 participants will receive the combination. The main goal is to see how many people's tumors shri…

This study tests a new drug called MDX2001 in people with advanced solid tumors that have spread. The main goals are to check the drug's safety and see if it can shrink tumors. About 285 adults with various cancers like lung, breast, or colon cancer will take part. This is an ear…

This phase 2 study is testing whether adding an experimental therapy called PRGN-2009 to the immunotherapy drug pembrolizumab can help shrink tumors in people with recurrent or metastatic cervical cancer that has stopped responding to pembrolizumab alone. About 24 adults with HPV…

This study tests a drug called HLX43 in 190 people with advanced cervical or ovarian cancer that came back or spread after initial treatment. HLX43 is designed to deliver a toxin directly to cancer cells by targeting a protein called PD-L1. The goal is to see if it can shrink tum…

This early-stage trial is testing a new drug called TGW101 in people with advanced solid tumors that have not responded to other treatments. TGW101 is given in two parts: an antibody-drug conjugate and a chemical trigger that activates it. The main goal is to check safety and fin…

This early-stage trial tests a new drug called KIVU-107 in 76 adults with advanced solid tumors that have not responded to standard treatments. KIVU-107 is an antibody-drug conjugate designed to target and kill cancer cells. The main goal is to find a safe dose and check for side…

This study tests a new drug called KRC-01, given as an injection directly into the tumor along with standard radiation therapy, for people with locally advanced cervical cancer. The goal is to see if the combination is safe and helps shrink tumors better than radiation alone. Abo…

This early-stage trial is testing a new treatment called VET3-TGI, a virus designed to infect and destroy cancer cells. It is being given alone or with the immunotherapy drug atezolizumab to 60 people with advanced solid tumors that have not responded to standard treatments. The …

This phase 2 trial is testing a combination of two drugs, Sacituzumab tirumotecan and QL1706, in 89 women with recurrent or metastatic cervical cancer that cannot be treated with surgery or radiation. The goal is to see if the combo can shrink tumors and improve survival. Partici…

This early-phase study tests a new drug called 177LuBetaBart in people with advanced solid tumors that have stopped responding to standard treatments. The drug is a radioactive antibody designed to seek out and destroy cancer cells. The study will enroll about 61 participants and…

This study compares a shorter, higher-dose radiation schedule (hypofractionated radiotherapy) to the standard longer course for women with locally advanced cervical cancer in Uganda. About 278 participants will receive either the shorter or standard radiation, plus chemotherapy a…

This study tests a new drug called ivonescimab in 50 people with advanced endometrial or cervical cancer that has worsened after standard chemotherapy. The drug targets two proteins (PD1 and VEGF) to help the immune system fight cancer and block tumor blood supply. Researchers wi…

This Phase 1 trial tests a new drug called BL-M07D1 in 280 adults with advanced HER2-positive cancers, including breast, lung, and stomach cancers. The study aims to find safe doses and check for early signs of tumor shrinkage. Participants must have tried at least two prior trea…

This early-stage trial tests whether a stool transplant (FMT) can help cancer patients who develop severe diarrhea or colon inflammation from immune-checkpoint inhibitor drugs. About 40 patients with various cancers will receive the transplant via colonoscopy. The main goal is to…

This phase 2 trial tests a new drug called YL202 in about 100 people with advanced solid tumors, including lung, colorectal, and cervical cancers. The drug is given through an IV and aims to shrink tumors or stop them from growing. Researchers will check how well it works and mon…

This early-phase study tests a new drug called STRO-004 in adults with advanced solid tumors that have not responded to standard treatments. The study has three parts: finding a safe dose of STRO-004 alone, testing that dose in more patients, and combining STRO-004 with another d…

This study tests an oral drug called NEO212 in people with specific brain tumors (astrocytoma, glioblastoma) or cancers that have spread to the brain. The goal is to find the safest dose and see if it helps control tumor growth. About 134 adults will take NEO212 alone or with sta…

This phase 2 trial is testing whether adding a precise radiation boost to standard treatment can shrink large cervical tumors more effectively. Seventeen participants with bulky squamous cell carcinoma will receive external radiation plus a targeted boost, followed by internal br…

This phase 2 trial is testing a shorter course of radiation therapy (hypofractionated IMRT) given alongside chemotherapy (cisplatin) for cervical cancer. The goal is to see if this approach can reduce the overall treatment time from the usual 7-8 weeks while still controlling the…

This study tests a new drug called CNSI-Fe(II), which is injected directly into tumors. It uses iron to trigger a type of cell death called ferroptosis, aiming to control advanced solid tumors like lung, pancreas, and colorectal cancers. The trial involves 54 adults whose current…

This study tests whether a same-day HPV screening and treatment approach can help prevent cervical cancer in women living with HIV in the Dominican Republic. 600 women will be randomly assigned to either the new same-day method or standard care. The goal is to see if more women c…

This study tests a new type of radiation called spatially fractionated radiation therapy for people with cervical cancer or pelvic cancer that has come back. It is for patients who cannot get the usual brachytherapy because of unusual anatomy or large tumors. The goal is to see i…

This early-phase trial is testing a new drug called NRM-823, alone or with immunotherapy, in people with advanced solid tumors like lung, ovarian, or breast cancer that haven't responded to standard treatments. The study aims to see if the drug is safe and tolerable. About 150 pa…

This early-phase trial tests MGC026, a biologic drug given by IV, in 250 adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, finding a safe dose, then expanding to see if the drug shrinks tumors. Participants receive u…

This study tests a drug called sacituzumab govitecan in 20 people whose cervical cancer has returned or persisted after at least one prior chemotherapy. The drug is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells. The main goal is to see how m…

This early-phase study tests a new drug called BL-B01D1 in people with advanced lung cancer or other solid tumors that have spread or cannot be removed. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. About 470 adults will tak…

This Phase II study tests a combination of three drugs—BL-B01D1, pembrolizumab, and possibly bevacizumab—in people whose cervical or endometrial cancer has come back or spread. The goal is to see if the combo shrinks tumors and to find the best dose. About 96 adults aged 18–75 wi…

This phase II trial is testing whether adding the immunotherapy drug serplulimab to standard chemoradiotherapy can help people with locally advanced cervical cancer live longer without their disease getting worse. About 216 participants who have not yet been treated will receive …

This study tests a shorter course of radiation therapy combined with chemotherapy for cervical cancer. The goal is to see if this approach is safe and effective, potentially reducing treatment time and improving outcomes. The trial will enroll 30 adults with stage II or III cervi…

This study tests a modified virus (KD01) that targets and kills cancer cells, given alone or with an immunotherapy drug (AK104). It includes 97 women with cervical or endometrial cancer, some of whom have not responded to standard treatments. The goal is to see if the virus is sa…

This study compares online adaptive radiotherapy (oART) to standard image-guided radiotherapy for cervical cancer. oART adjusts the radiation beam daily based on the tumor's changing shape and position. The goal is to reduce side effects like bowel and bladder problems while keep…

This study tests two experimental drugs, ZG005 and gecacitinib (with or without bevacizumab), in 120 women with advanced cervical cancer. The goal is to see if the combination is safe and can shrink tumors. Participants must be 18-75 and have a confirmed diagnosis of advanced cer…

This early-stage trial is testing a new drug called DR-0202, a bispecific antibody, in people with advanced solid tumors (such as breast, lung, and pancreatic cancers) that have not responded to at least two prior treatments. The study aims to find a safe dose and see if the drug…

This study tests a new tablet called ABP1011T in people with advanced solid tumors, including small cell lung cancer and others like esophageal or bladder cancer. Participants take one pill daily in 21-day cycles. The goal is to see if the drug can shrink tumors and how safe it i…

This study compares proton therapy to standard photon radiation for cervical cancer patients who need extended-field radiation. The goal is to see if proton therapy causes less severe lymphopenia (low white blood cell count) and fewer side effects. About 44 participants with adva…

This study tests whether using MRI scans to guide brachytherapy (a type of internal radiation) can better target tumors in gynecologic cancers like cervical, uterine, vaginal, vulvar, and bladder cancers. The goal is to see if MRI guidance reduces radiation exposure to nearby hea…

This phase 2 trial is testing whether adding the immunotherapy drug camrelizumab to standard chemotherapy can help prevent cervical cancer from coming back in patients whose cancer had spread to lymph nodes. About 59 participants will receive the combination after surgery. The ma…

This early-phase trial tests a new drug called MT-4561 in about 27 people with advanced solid tumors (like lung, breast, or pancreatic cancer) who have no standard options left. The main goals are to find a safe dose and see if the drug can shrink tumors. It is a first-in-human s…

This early-phase study tests a new treatment called GC203 TIL for people with advanced solid tumors (cancers in organs like the breast, lung, or gut) that have not responded to standard therapies. The treatment uses a patient's own immune cells, which are modified in a lab to bet…

This study tests a new drug called YL202 in people with advanced solid tumors, including lung, breast, and head/neck cancers. The goal is to see if the drug can shrink tumors and control the disease. About 200 participants will receive the drug, and researchers will monitor safet…

This early-stage study is testing a new therapeutic vaccine called TI-0093 in 12 adults with HPV-16 positive cancers that have returned or spread. The vaccine is given as a series of five shots over about a month. The main goals are to check safety, find the best dose, and see if…

This study tests a drug called belzutifan in people with a rare, hard-to-treat type of gynecologic cancer called clear cell carcinoma. The goal is to see if the drug can shrink tumors or stop them from growing. About 32 participants will receive the drug, and researchers will mon…

This study tests whether a combination of two drugs, VS-6766 and defactinib, can shrink or control certain gynecological cancers that have come back. It includes women with endometrioid, ovarian, or cervical cancers that have specific gene changes (RAS, BRAF, or NF1). The goal is…

This study tests whether combining two drugs, pembrolizumab and lenvatinib, can shrink tumors in people with advanced cervical cancer that has stopped responding to initial treatment. The trial enrolls 35 adults whose cancer has spread or cannot be removed by surgery. The goal is…

This early-stage trial tests a new type of immunotherapy called CD70-targeted CAR-T cells in people with advanced solid tumors, including kidney, lung, ovarian, and thyroid cancers. The treatment involves taking a patient's own immune cells, engineering them to recognize and atta…

This phase II trial tests two experimental drugs, BL-B01D1 and SI-B003, alone or together, in 130 women with recurrent or metastatic cervical cancer that hasn't responded to standard treatments. The goal is to see if these drugs can shrink tumors or slow the cancer's growth. Part…

This early-phase trial is testing a new therapy called Meta10-TIL for people with advanced solid tumors that have not responded to at least one prior treatment. The therapy uses a patient's own tumor-fighting immune cells, which are modified in the lab to work better, and then gi…

This early-stage trial tests a new drug called NX-1607 in adults with advanced cancers that have not responded to standard treatments. The study aims to find a safe dose and see if the drug can shrink tumors. It includes people with several cancer types, such as ovarian, lung, an…

This study is testing whether surgically removing enlarged lymph nodes in the pelvis and abdomen before standard chemoradiation can help people with stage IIICr cervical cancer live longer without the cancer growing. About 452 participants will be randomly assigned to either have…

This study investigates whether urine samples can be used to screen for cervical cancer in women living with HIV. Researchers will compare the accuracy of urine HPV testing with self-collected and provider-collected samples to detect cervical precancer (CIN2 or worse). The goal i…

This study is testing a new, affordable AI system to screen for cervical cancer in low- and middle-income countries. The AI analyzes urine samples and cervical images to detect high-risk HPV and precancerous changes. About 3,200 unscreened women aged 25-49 in Zimbabwe will take p…

This study is testing a new type of PET scan that uses special radioactive tracers to find and map solid tumors in the body. The tracers target a protein called Trop2, which is often found on cancer cells. Researchers will enroll 400 people with various cancers (including bladder…

This study is testing a new imaging agent called 18F-T2, which is designed to highlight tumors that produce a protein called CAIX. About 200 adults with various cancers (like kidney, lung, or breast cancer) will receive an injection of 18F-T2 and then undergo a PET/CT scan. The g…

This early-stage trial tests a radioactive imaging agent called RAD301 in 9 people: healthy volunteers and patients with pancreatic, lung, esophageal, cervical, endometrial, or ovarian cancer. The goal is to see how safe it is and how it travels through the body. If it works, it …

This study looks at whether giving women at-home kits to test for HPV (a virus that can cause cervical cancer) makes it easier for them to get screened. About 100 women who are overdue for screening will receive a kit and be asked to return a sample by mail. Researchers will comp…

This study aims to develop a screening test that uses a vaginal swab and blood sample to find DNA markers for endometrial, ovarian, and cervical cancers. Researchers at Mayo Clinic will enroll over 3,000 women to see if the test can accurately detect these cancers at an early sta…

This study is testing whether a self-administered Pap smear is as accurate as the traditional one done by a healthcare provider. Researchers will recruit 250 women in rural Alabama who need routine cervical cancer screening. Each woman will do a self-collected sample right before…

This study is testing whether giving women a simple self-sampling kit to use at home can increase the number of women who get screened for cervical cancer. The trial will enroll 15,000 women in Czech Republic, especially those who haven't had a Pap smear in over 3 years. Particip…

This study tests a new device called the Calla introducer for cervical cancer screening. Researchers want to see if women prefer it over the standard speculum used during Pap smears. About 305 healthy women aged 21-65 will participate. The goal is to improve comfort and screening…

This study is testing whether special light-based devices can detect cervical cancer by identifying unique optical signatures of abnormal tissue. Researchers will use three different devices—a bench-top spectrometer, a portable spectrometer, and a pocket-sized colposcope—on 350 w…

This study in Mozambique is testing two new technologies to improve cervical cancer screening and diagnosis. Researchers will compare a rapid HPV test and a special imaging device against standard methods in about 678 women. The goal is to find faster, more accurate ways to detec…

This study is testing a blood test that looks for DNA signals from 20 different cancers, including lung, breast, and colon cancer. Researchers will see if the test can find cancer early, detect any cancer left after treatment, and catch a relapse before it shows up on scans. The …

This study tests Cellvizio, a device that provides real-time, high-resolution views of tissues during gynecological surgery. Researchers want to see if it can help diagnose lesions and check surgical margins more accurately. The study will enroll 80 women undergoing laparoscopic …

This study is testing a small, AI-powered camera called the Pocket colposcope to see if it can accurately detect early signs of cervical cancer in women who have tested positive for HPV. About 1,054 women in Kenya will use the device during a routine exam. The goal is to find a s…

This study explores whether women can accurately collect their own samples for HPV testing, which could make cervical cancer screening easier and more accessible. The research focuses on minority women who are often under-screened, using community health workers to help with the …

This study is testing a blood test called NavDx that looks for tiny pieces of HPV DNA shed by cancer cells. The goal is to see if this simple blood draw can accurately detect cervical cancer and precancer, and monitor how patients respond to treatment. The study will enroll 100 w…

This study tests a program called SAKHI HPV for women in India who have both HPV and HIV. The program provides support from community health workers, group sessions, and nutrition education to help women stay healthy and reduce their risk of cervical cancer. Researchers will comp…

This study tests a patient navigation program to help women in Senegal overcome barriers to cervical cancer screening and follow-up care. Researchers will work with community health workers to guide women through the process, addressing stigma and misinformation. The goal is to i…

This study tests whether a general practitioner's encouragement can increase the number of women who get screened for cervical cancer. Over 11,000 women aged 25-65 in France who are behind on screening will be involved. The goal is to see if a simple conversation with their famil…

This study checks how well the HPV vaccine prevents cervical HPV infection in women in Sikkim, India, about 7 years after the vaccine was introduced. Researchers will collect cervical samples from 5,500 married women aged 18-22 and compare infection rates to those before vaccinat…

This study tests whether cancer patients can complete a supervised exercise program from home using video calls. The program includes resistance training with dumbbells and aerobic exercise. Researchers want to see if this approach is practical and helps patients maintain functio…

This study is testing a precise type of radiation (proton beam) given to the pelvis after surgery for cervical, uterine, or endometrial cancer. The goal is to see if it causes fewer bowel side effects than standard radiation. About 25 adults who need pelvic radiation after surger…

This study tests whether using cold wraps plus compression (cryocompression) on hands and feet during chemotherapy can reduce nerve damage (peripheral neuropathy) in people with gynecologic cancer. About 190 participants will be randomly assigned to receive either cryocompression…

This study tests a personalized physical activity program for women over 60 with gynecologic cancers who are receiving chemotherapy or other systemic treatments. The program includes a wearable activity tracker and a smartphone app, plus optional features like an exercise partner…

This study tests whether special pelvic floor exercises, guided by a biofeedback device, can improve sexual function in women who had radiation for cervical cancer. Sixty survivors with sexual problems will be randomly assigned to either biofeedback-assisted training or standard …

This study is testing whether a shorter course of pelvic radiation after surgery works as well as the standard longer schedule for people with cervical or endometrial cancer. The shorter schedule means fewer hospital visits and less time in treatment. About 120 participants will …

This study tests whether Reiki therapy can reduce anxiety and pain in people receiving brachytherapy for gynecologic cancers. 70 participants will either receive Reiki or standard care during their treatment. Researchers will measure changes in anxiety, pain, and mood using quest…

This study tests whether using a virtual reality headset during brachytherapy (a type of internal radiation for cervical cancer) can reduce pain, anxiety, and the need for medication. Twenty women will try VR during one treatment session and compare it to a session without VR. Th…

This study tests whether pelvic floor physical therapy can reduce bowel and bladder control problems that often happen after radiation for cervical cancer. Twenty-eight women who are getting pelvic radiation will start physical therapy four weeks after finishing radiation. The th…

This study looks at possible eye-related side effects in people with cervical cancer that has returned or spread, who are being treated with the drug TIVDAK. About 100 participants will receive TIVDAK every 3 weeks and undergo regular eye exams before, during, and after treatment…

This study looks at whether people with certain cancers prefer getting their immune therapy as a shot under the skin (subcutaneous) or through a needle in a vein (intravenous). About 880 adults who are already eligible for standard treatments like nivolumab or pembrolizumab will …

This study tests a new way of giving radiation for cervical cancer. Instead of using the same plan for weeks, an AI adjusts the radiation daily based on the tumor's position, and weekly MRI scans help guide it. The goal is to reduce side effects like bladder and bowel problems. A…

This study looks at whether adding pelvic floor physical therapy before standard radiation treatment can help reduce pain and sexual problems in women with cervical, vaginal, vulvar, uterine, or anal cancer. About 20 participants will receive education on using a vaginal dilator …

This study explores whether acupuncture can reduce nerve pain and numbness caused by chemotherapy in people with gynecologic, urologic, or rectal cancers. About 75 participants will be randomly assigned to receive real acupuncture, sham acupuncture, or usual care for 6 weeks. The…

This study compares a fast, 1-week radiation treatment to a standard 6-8 week schedule for reducing pain in people with advanced cervical cancer that cannot be cured. The goal is to see if the shorter schedule provides similar or better pain relief. The trial is recruiting 230 pa…

This study tests whether a daily probiotic pill (Pendulum Glucose Control) can safely reduce stomach and bowel problems in people receiving radiation for cancers of the pelvis, such as prostate, gynecologic, or lower GI cancers. About 20 adults will take the probiotic during thei…

This study tests a program called CARES that provides nurse navigators and counselors to rural cancer patients. The goal is to see if this support helps patients start and finish treatment more quickly and improves their quality of care. About 320 adults with solid tumors like lu…

This study tests whether a non-invasive treatment called transcutaneous electrical acupoint stimulation (TEAS) can help women who have trouble emptying their bladder after radical hysterectomy for cervical cancer. 76 participants will either receive real TEAS or a sham version al…

This early study tests whether a gel spacer, already used in prostate cancer, can be safely placed between the cervix and rectum in 14 women with cervical cancer receiving standard chemoradiation. The goal is to see if the gel creates enough space to reduce radiation exposure to …

This study is testing whether a shorter course of pelvic radiation (called hypofractionation) is safe for women with endometrial cancer. The researchers will find the best dose and see if it reduces bowel and urinary side effects. About 100 women who have already had surgery will…

This study tests whether a mobile cognitive training app can reduce 'chemobrain'—memory and thinking problems caused by chemotherapy—in people with gynecologic cancers. Sixty-four participants will use the app on their own phones while undergoing chemotherapy and complete thinkin…

This study tests whether a pre-surgery program of exercise and a dietary supplement called Ocoxin can improve recovery for 100 women undergoing surgery for gynecologic cancers like endometrial, ovarian, or cervical cancer. Participants will follow an enhanced recovery protocol (E…

This study looks at whether using the Headspace mindfulness app before surgery or chemoradiation can help people with endometrial or cervical cancer use fewer opioid painkillers. About 120 participants will be randomly assigned to use the app or not. The goal is to see if mindful…

This study looks at the bacteria living in the mouth, stool, and tumors of Colombian adults with advanced cancers of the stomach, colon, breast, cervix, or head and neck who are starting immunotherapy as standard care. Researchers will compare these microbial profiles to those of…

This study will test tumor samples from 350 adults with gynecological cancers (endometrial, ovarian, cervical, vulvar, and vaginal) to see how often they have high levels of the HER2 protein. Researchers will use two standard lab tests to measure HER2. The goal is to learn how co…

This study in South Africa works with women who have HIV and abnormal Pap results to find out why some don't follow up for cervical cancer care. Researchers will interview patients and providers, then create a short counseling and navigation program. They will test if the program…

This study is observing 300 women with female sexual organs who are receiving radiotherapy for certain cancers. Researchers want to understand why some patients have more sexual side effects than others. They will track sexual quality of life and look at radiation doses to find p…

This study enrolls 400 adolescents and young adults (ages 18-39) recently diagnosed with various cancers. Participants are randomly assigned to either choose which health-related questions they answer or receive a fixed set of questions. The goal is to see if giving patients a ch…

This study tests whether giving gynecologic cancer patients a list of questions to ask their doctor improves their confidence, reduces distress, and builds trust. About 70 adults with newly diagnosed or suspected gynecologic cancer will either receive the question list or usual c…

This study looks at tumor samples from 2,100 Chinese patients with lung, gynecologic, bile duct, or bladder cancers. Researchers will compare different HER2 testing methods to see how well they agree with each other. The goal is to improve the accuracy of HER2 testing, which help…

This study follows 80 cervical cancer patients who receive brachytherapy (internal radiation) to see if they develop post-traumatic stress disorder (PTSD). Participants fill out questionnaires about PTSD, anxiety, depression, quality of life, and sexual health over 5 years. The g…

This pilot study is testing whether a 7-day integrative oncology retreat called 'Via Shalva' is practical and helpful for women who have finished primary treatment for breast or gynecologic cancer. Thirty participants will either attend the retreat or receive usual follow-up care…

This study aims to validate a gene test that identifies oxygen-starved (hypoxic) tumours in bladder and prostate cancer patients. About 30 participants will provide tumour samples and blood, and some will have MRI scans. The goal is to see if this test can help doctors choose mor…

This study is testing whether HPV DNA found in blood and urine can be used as a simple, non-invasive way to detect cervical cancer and monitor how well treatment is working. Researchers will collect samples from 30 women newly diagnosed with cervical cancer before and after their…

This study follows 200 women with gynecologic cancer and their partners to see how sexual function changes over time. Researchers use questionnaires at diagnosis, 6 months, and 12 months after treatment. The goal is to understand when sexual counseling might be most helpful, with…

This study in Botswana tests different outreach strategies to help women with cervical cancer start treatment within 90 days. Researchers will compare clinic calls, direct patient contact, and text message reminders. The goal is to find the best way to close the gap between diagn…

This study tests whether artificial intelligence can help more women in Occitanie, France, complete cervical cancer screening. About 3,000 women aged 30-65 who haven't been screened recently will be invited to use a self-sampling kit. The goal is to see if AI-assisted decision-ma…

This study looks at whether a special PET scan and a blood test for HPV can detect any remaining cervical cancer cells after standard chemoradiation. About 64 people with cervical cancer will be followed after their usual treatment. The goal is to see if these tests can predict i…

This study looks at whether a blood test can detect HPV DNA in people with HPV-related anal or cervical cancer who are receiving radiation therapy. Researchers will collect blood samples before, during, and after treatment to see if the virus's genetic material shows up and if it…

This study looks at women who had radiation therapy for cervical or endometrial cancer to see how often they experience long-term side effects in the bowel or bladder. Researchers will review medical records of 300 patients treated at Tata Memorial Hospital. The goal is to unders…

This study looks back at medical records of 350 people with cervical cancer that has come back or spread to a few spots. The goal is to see how well treatments like radiation or surgery work, alone or with chemotherapy. Researchers want to find out which patients benefit most fro…

This study is testing two blood tests that look for HPV DNA and RNA to see if they can track how well cervical cancer responds to surgery, radiation, and chemotherapy. Researchers will enroll 55 adults with HPV-related cervical cancer and compare the test results with standard im…

This study is testing whether liquid biopsies (blood tests that look for bits of HPV and tumor DNA) can help doctors monitor treatment and spot early signs of cancer returning in people with HPV-related cervical and oropharyngeal cancers. Researchers will follow 480 participants …

This study looks at whether changes in a blood marker called CRP can help predict how well immunotherapy works in women with advanced gynecologic cancers (cervical, endometrial, ovarian, or vulvar). Researchers will track CRP levels in 120 women receiving immunotherapy plus chemo…

This study looks at better ways to provide cervical cancer screening and treatment to women living with HIV in Nigeria. About 2,400 women will take part. Researchers will compare two sets of strategies to see which works best for getting women screened and treated. The goal is to…

This study aims to see if a newer type of scan, called PET/MRI, is better than the standard PET/CT scan at finding cancer spread in lymph nodes for people with cervical cancer. About 50 adults with stage IB2 to IVA cervical cancer will be enrolled. Researchers will compare the ac…

This study looks at how the dose and storage conditions of a dye called indocyanine green (ICG) affect its ability to find sentinel lymph nodes during surgery for cervical, endometrial, and vulvar cancers. Researchers will enroll 30 patients to see which approach works best and s…

This study looks at whether hospitals in India are following standard guidelines for treating cervical cancer with radiation and chemotherapy. Researchers will review records from over 600 patients treated at multiple centers to see how often the recommended care is given. The go…

This study collects tumor and blood samples from over 1,000 people with certain cancers (ovarian, breast, head and neck, cervical, vulva, and sarcoma). Researchers will analyze the samples to find links between genetic changes, the immune system, and how the cancer behaves. Parti…

This study looks at whether peer education and support can help more adolescents and young adults (ages 15-39) living with HIV get screened for cancer and stick with their cancer treatment. Researchers will work with 4,100 participants in Zambia to improve early diagnosis and tre…

This study looks at the best times to send messages that encourage physical activity to older cancer survivors (65+) who have chronic pain. About 50 participants will wear an activity tracker and rate their pain four times a day using a smartphone app. The goal is to see if certa…

This study tests a program called DADA-LINK to help more women in Kenya get screened for cervical cancer. The program includes HPV self-sampling kits, a care navigator to guide patients, and a phone app to track care. About 1,980 women aged 25-49 will take part, and researchers w…

This study explores whether a simple at-home HPV test can help women in war-torn Ukraine get screened for cervical cancer. About 1,000 women aged 30-60 who haven't had a recent negative HPV test will receive a self-sampling kit. The goal is to see if this approach is practical an…

This study compares two common risk assessment tools—the Charlson Comorbidity Index (CCI) and the POSSUM score—to see which better predicts complications in women undergoing surgery for gynecologic cancers. Researchers will track complications, hospital stay length, and 30-day de…

This study aims to learn how gene and protein changes in gynecologic tumors affect cancer behavior and treatment response. Researchers will collect tumor tissue and blood samples from 1,000 people with ovarian, uterine, cervical, or other gynecologic cancers. The goal is to bette…

This study works with clinics in Massachusetts to help people in underserved communities manage weight, get cancer screenings, and improve mental health. It includes 3,600 adults who speak English or Spanish and have obesity, are due for colorectal or cervical cancer screening, o…

This study is testing a mobile app called mSaada that helps community health workers educate women, track screening, and send reminders for cervical cancer screening. The trial involves 6,000 women and health workers across 12 health facilities in western Kenya. The goal is to se…

This study is for people with cervical or pancreatic cancer who are scheduled to receive chemoradiotherapy. Researchers will collect tumor samples, blood, and imaging data before, during, and after treatment to see how the tumor environment changes over time. The goal is to learn…

This study will collect blood and tumor samples from 1,100 people with various cancers, including head and neck, ovarian, cervical, lung, and brain cancers. Researchers want to learn how immune cells called T cells behave in these tumors. The goal is to better understand why some…